Pervious Polymersomes For Antioxidant Enzyme Delivery

Pervious polymersomes encapsulate antioxidant agents while allowing reactive oxygen species to enter through diblock copolymer-defined channels.
Problem:
Reactive oxygen species and oxidative stress are associated with osteoarthritis development and myocardial injury. Direct use of antioxidant enzymes is challenging due to insufficient delivery systems. Enzyme payloads may require protection and retention while remaining accessible to reactive oxygen species. These limitations create a need for delivery systems that support antioxidant enzyme treatment.
Solution:
Dr. Zhiliang Cheng and his team developed a technology that uses a pervious polymersome that encapsulates an anti-reactive oxygen species agent. Channels formed by a channel diblock copolymer allow reactive oxygen species to pass into the polymersome. The channels are arranged to retain at least some of the agent within the polymersome. The technology supports therapeutic compositions, administration methods, formation methods, and injector-based kits.
Technology Overview:
The polymersome can include an amphiphilic diblock copolymer bilayer and a channel diblock copolymer. Supported amphiphilic diblock copolymers include PEG-PBD, PEG-PCL, PEG-PLA, and PEG-PLGA. The channel diblock copolymer can include PEG-PPO. Supported anti-reactive oxygen species agents include enzymes or enzyme mimics, including superoxide dismutase or catalase.
Advantages:

• Encapsulates antioxidant agents within a pervious polymersome
• Allows reactive oxygen species to enter through channels while retaining at least some payload
• Supports enzyme and enzyme mimic payloads, including superoxide dismutase and catalase
• Provides composition, treatment, formation, and kit embodiments
• Supports injection-based administration using an injector, syringe, or cannula 

Applications:

• Myocardial ischemia: The technology is described for administration to myocardium in subjects having an ischemic condition.
• Osteoarthritis: The technology is described for administration to joints in subjects optionally having osteoarthritic conditions.
• Septic conditions: The technology is described for administration to subjects having septic conditions.
• Respiratory conditions: The technology is described for administration to subjects having respiratory conditions, including acute respiratory distress syndrome.
• Dermatologic conditions: The technology is described for administration to subjects having dermatologic conditions. 

Intellectual Property:

• US Application US20230144866A1 

Docket #21-9618